Tocilizumab: A review of its safety and efficacy in rheumatoid arthritis

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

Volumn 3, Issue , 2010, Pages 81-89

  Jones, Graeme ^a   Ding, Changhai ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Clinical trials; Interleukin 6; Rheumatoid; Therapy

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; PLACEBO; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; CARDIOPULMONARY INSUFFICIENCY; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; DIGESTIVE SYSTEM PERFORATION; DISEASE DURATION; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART MUSCLE ISCHEMIA; HERPES VIRUS INFECTION; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; INJECTION SITE REACTION; LIVER FUNCTION TEST; LUNG CANCER; MYCOSIS; NEUTROPENIA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS INFECTION; TH17 CELL; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79751520384     PISSN: 11795441     EISSN: 11795441     Source Type: Journal    
DOI: 10.4137/CMAMD.S4864     Document Type: Review

References (25)

1. Jones G, Halbert J, Crotty M, et al. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo- controlled trials. Rheumatology (Oxford). 2003;42:6-13.
2. Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev Recent Clin Trials. 2006;1:193-200.
3. Imagawa T, Mori M, Takei S, et al. Efficacy and safety of tocilizumab, an anti- IL-6 receptor monoclonal antibody; in patients with polyarticular or oligoarticular onset juvenile idiopathic arthritis. Arthritis Rheum. 2006;54:S168.
4. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731-40.
5. Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti- human interleukin-6 receptor antibody), unveils the mysterious etiology of immunemediated inflammatory diseases. Biol Pharm Bull. 2007;30:2001-6.
6. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther. 2006;8:S2.
7. Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti- interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003;30:1426-35.
8. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12-9.
9. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of Active Controlled Monotherapy Used for Rheumatoid Arthritis, an IL-6 inhibitor (SAMURAI):-Evidence of clinical and radiographic benefit from an X-Ray Reader-Blinded Randomized Controlled Trial of TCZ. Ann Rheum Dis. 2007;66:1162-7.
10. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-29.
11. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009;68:1580-4.
12. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with TCZ in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987-97.
13. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The TCZ in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-80.
14. Emery P, Keystone E, Tony HP, et al. IL-6 Receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre Randomised Placebo Controlled Trial. Ann Rheum Dis. 2008;67:1516-22.
15. Jones G, Sebba A, Gu J, et al. Comparison of TCZ monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010;69:88-96.
16. Kremer JM, Fleischmann RM, Halland AM, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: the LITHE study. Arthritis Rheum. 2008;58:S4031.
17. Jones G. The AMBITION trial: Tocilizumab monotherapy for rheumatoid arthritis. Exp Rev Clin Immunol. 2010;6:189-95.
18. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum. 2010;62:33-43.
19. Smolen JS, Beaulieu AD, Dikranian A, et al. Safety of tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum. 2008;58:S784.
20. Kremer JM, van Vollenhoven RF, Ridley DJ, et al. Relationship between patient characteristics and the development of serious infections in patients receiving tocilizumab: results from long-term extension studies with a follow- up duration of 1.5 years. Arthritis Rheum. 2008;58:S783-4.
21. Kremer JM, Joh AK, Malamet R, Keystone EC. Hepatic aminotransferases and bilirubin levels during tocilizumab treatment of patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum. 2008;58:S783.
22. Genovese MC, Smolen JS, Emery P, et al. Lipid and inflammatory biomarker profiles in patients receiving tocilizumab for rheumatoid arthritis: analysis of five phase 3 clinical trials. Arthritis Rheum. 2008;58:S531.
23. Genovese MC, Smolen JS, Emery P, et al. Concomitant use of statins in tocilizumab-treated patients with rheumatoid arthritis with elevated low density lipoprotein cholesterol: analysis of five phase 3 clinical trials. Arthritis Rheum. 2008;58:S785.
24. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68:460-9.
25. Ramos-Remus C, Genovese MC, Harre RA, et al. Low immunogenic potential of tocilizumab in patients with rheumatoid arthritis: analysis of four phase 3 clinical trials. Arthritis Rheum. 2008;58:S534.